In 2006, the Centers for Medicare and Medicaid Services (CMS) released the Lower Cash Price Policy anticipating that some Medicare Part D prescription drug plan beneficiaries would find lower costing formulary drugs at network pharmacies using pharmacy drug discount cards or other discount program during their Initial Deductible or Coverage Gap phase (Donut Hole) - where the Medicare beneficiary is 100% responsible for the cost of their Medicare Part D drugs.
If lower-priced, discounted drug prices were found, the Medicare Part D beneficiary could purchase the medication at the lower price without using their Medicare Part D plan to record the purchase. The Medicare beneficiary counld then submit the purchase receipts for their non-Part D purchases to their Medicare Part D plan. If the Medicare Part D plan found the medications were on their formulary and purchased at a network pharmacy, the Part D beneficiary would receive credit for the purchase toward their total drug spending or TrOOP limit (the Donut Hole Exit Point).
As noted in the 2006 CMS memo below, the Lower Cash Price Policy was specifically limited "to ensure that enrollees:
(1) do not unwittingly forego plan funded coverage, which in most cases will be the lowest price available given the price concessions built into the plan’s negotiated prices;
(2) have the benefit of plan drug utilization review and other safety edits that can only be provided if the plan adjudicates the claim; and
(3) proceed through the benefit as quickly as possible in order to reach catastrophic coverage."
The Lower Cash Price Policy was then updated in the 2010 and 2013 Medicare Prescription Drug Benefit Manual, Chapter 14, Coordination of Benefits, adding the consideration of enhanced Medicare Part D plans that have a $0 deductible and some form of coverage in the Donut Gap or Donut Hole. You can read more here:
How does the Lower Cash Price Policy apply to you?
Medicare Part D plans include the Lower Cash Price Policy into coverage benefits and the plan' Evidence of Coverage document explains when the policy is applicable and how a plan member can send receipts to obtain credit for their non-Part D drug purchases during the Initial Coverage phase or Coverage Gap.
For instance, a Medicare Part D plan might state in their Evidence of Coverage document:
"In some cases, you [the Medicare plan beneficiary] should send copies of your receipts to us [the Medicare Part D plan] to help us track your out-of-pocket drug costs
There are some situations when you should let us know about payments you
have made for your drugs. In these cases, you are not asking us for
payment [reimbursement]. Instead, you are telling us about your payments so that we can
calculate your out-of-pocket costs [or TrOOP] correctly. This may help you to
qualify for the Catastrophic Coverage Stage more quickly. [If you exit the Donut Hole and enter the Catastrophic Coverage phase, you may save more than 95% on the retail cost of your medications.]
Here are two situations when you should send us copies of receipts to let us know about payments you have made for your drugs:
1. When you buy the drug for a price that is lower than our price
Sometimes when you are in the Deductible Stage and Coverage Gap Stage
you can buy your drug at a network pharmacy for a price that is lower
than our price.
-
For example, a pharmacy might offer a special price on the drug. Or
you may have a discount card that is outside our benefit that offers a
lower price.
- Unless special conditions apply, you must use a network pharmacy in these situations and your drug must be on our Drug List [or formulary].
- Save
your receipt and send a copy to us so that we can have your
out-of-pocket expenses count toward qualifying you for the Catastrophic
Coverage Stage. [Instructions of how to send us the receipts is usually included within this section.]
- Please note: If you are in the Deductible Stage
and Coverage Gap Stage, we may not pay for any share of these drug
costs. But sending a copy of the receipt allows us to calculate your
out-of-pocket costs correctly and may help you qualify for the
Catastrophic Coverage Stage more quickly.
2. When you get a drug through a patient assistance program offered by a drug manufacturer
Some members are enrolled in a patient assistance program [PAP] offered
by a drug manufacturer that is outside the plan benefits. If you get any
drugs through a program offered by a drug manufacturer, you may pay a
copayment to the patient assistance program.
- Save your
receipt and send a copy to us so that we can have your out-of-pocket
expenses count toward qualifying you for the Catastrophic Coverage
Stage.
- Please note: Because you are getting
your drug through the patient assistance program and not through the
plan’s benefits, we will not pay for any share of these drug costs. But
sending a copy of the receipt allows us to calculate your out-of-pocket
costs correctly and may help you qualify for the Catastrophic Coverage
Stage more quickly.
Since you are not asking for payment in the two cases described above, these situations are not considered coverage decisions. Therefore, you cannot make an appeal if you disagree with our decision."
[Source: CMS Model 2016 ANOC and EOC document for PDPs] [highlights and emphasis added]
The following is the original 2006
CMS Lower Cash Pricing Policy. The links above provide updates as given in the Medicare Part D Manual.
DEPARTMENT OF HEALTH & HUMAN SERVICES
Centers for Medicare & Medicaid Services
7500 Security Boulevard
Baltimore, Maryland 21244-1850
CENTER FOR BENEFICIARY CHOICES
October 11, 2006
Memorandum To: All Part D Sponsors
Subject: HPMS Q & A - Lower Cash Price Policy
From: Cynthia Tudor, Ph.D., Director, Medicare Drug Benefit Group
The following question and answer on the lower cash price policy has been revised and updated in the Frequently Asked Questions Database on the CMS website at http://questions.cms.hhs.gov.
Q: What should an individual do if he or she is able to obtain a better price on a covered Part D drug at the point of sale than the negotiated price charged by his or her Part D plan if he/she is in the coverage gap or deductible phase of his or her benefit? Will that lower amount at the point of sale count toward the enrollee’s TrOOP balance?
A: Although we expect it to happen rarely, an individual may be able to obtain a lower price at a network pharmacy than that which his or her plan charges (the plan’s negotiated price) in any applicable coverage gap or deductible. This may be possible if the pharmacy is offering a “special” price or other discount for all customers, or if the beneficiary using a discount card, and the beneficiary is in any applicable coverage gap or deductible phase of his or her Part D benefit and is able to receive a better cash price for a covered Part D drug at a network pharmacy than the plan offers via its negotiated price. In this situation, he or she may purchase that covered Part D drug without using his or her Part D benefit or a supplemental card. The enrollee’s purchase price for the discounted drug will count toward total drug spend under his or her Part D benefit and TrOOP balance provided the Part D plan finds out about it.
The enrollee must take responsibility for submitting the appropriate documentation to his or her plan in order to have the amount count toward his or her total drug spend and TrOOP balances.FN1
Plans must accommodate the receipt of such information directly from enrollees and adjust total drug spend and TrOOP balances accordingly consistent with their established processes and clear instructions for enrollee paper claim submissions. These processes and instructions should be designed to distinguish between claims submitted for: (1) out-of-network coverage; (2) adjustment to TrOOP balances based on wraparound payments made by supplemental payers not previously submitted to the plan; (3) documentation submitted for a purchase made via a discount card or other special cash discount outside the Part D benefit in any applicable deductible or coverage gap phase of the benefit; and (4) documentation submitted for a nominal copayment assessed by a PAP sponsor operating outside the Part D benefit for assistance provided with covered Part D drug costs.
We note that this policy does not apply in any phase of an enrollee’s Part D benefit in which he or she is liable for any less than 100 percent cost-sharing. In other words, it does not apply outside of any applicable coverage gap or deductible phase of his or her benefit. We have limited the policy’s applicability in order to ensure that enrollees: (1) do not unwittingly forego plan funded coverage, which in most cases will be the lowest price available given the price concessions built into the plan’s negotiated prices; (2) have the benefit of plan drug utilization review and other safety edits that can only be provided if the plan adjudicates the claim; and (3) proceed through the benefit as quickly as possible in order to reach catastrophic coverage. It is unlikely that this policy is likely to be a significant source of savings for most enrollees, particularly since, if an enrollee fails to submit even one claim for a purchase made under the circumstances explained above, it is almost certain he or she will ultimately spend more than he or she would have under his or her plan’s negotiated prices.
We also note that organizations or entities offering discount card or other discounted price arrangements must comply with all relevant fraud and abuse laws, including, when applicable, the Federal anti-kickback statute and the civil monetary penalty prohibiting inducements to beneficiaries. The HHS Office of the Inspector General (OIG) enforces Federal fraud and abuse statutes, and all questions regarding the compliance of specific arrangements with these statutes should be referred to the OIG.
Please contact Alissa DeBoy at (410) 786-6041 if you have any questions about this guidance.
FN1 We note that in cases where a pharmacy offers a lower price to its customers throughout a benefit year, this
would not constitute a "lower cash price" situation that is the subject of this guidance. For example, Walmart recently introduced a program offering a reduced price for certain generics to its customers. The low Walmart price on these specific generic drugs is considered
Walmart’s “usual and customary” price, and is not considered a one-time "lower cash" price. Part D sponsors consider this lower amount to be “usual and customary” and will reimburse Walmart on the basis of this price. To illustrate, suppose a Plan's usual negotiated price for a specific drug is $10 with a beneficiary copay of 25% for a generic drug. Suppose Walmart offers the same generic drug throughout the benefit for $4. The
Plan considers the $4 to take the place of the $10 negotiated price. The $4 is not considered a lower cash price, because it is not a one-time special price. The Plan will adjudicate Walmart’s claim for $4 and the beneficiary will pay only a $1 copay, rather than a $2.50 copay. This means that both the Plan and the beneficiary are benefiting from the Walmart “usual and customary” price, and the discounted Walmart price of the drug is actually offered within the Plan’s Part D benefit design. Therefore, the beneficiary can access this discount at any point in the benefit year, the claim will be adjudicated through the Plan's systems, and the beneficiary will not need to send documentation to the plan to have the lower cash price count toward TrOOP. [highlighted emphasis added]